Published in J Steroid Biochem Mol Biol on May 13, 2013
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst (2015) 1.41
Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study. Cancer Causes Control (2015) 0.76
Comparison of Estimates between Cohort and Case-Control Studies in Meta-Analyses of Therapeutic Interventions: A Meta-Epidemiological Study. PLoS One (2016) 0.75
Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012. CMAJ Open (2016) 0.75
Body size over the life-course and the risk of endometrial cancer: the California Teachers Study. Cancer Causes Control (2016) 0.75
Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry. Horm Mol Biol Clin Investig (2015) 0.75
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 6.26
Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet (2005) 5.20
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer (1988) 3.07
Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst (1997) 2.92
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol (1995) 2.30
Increasing incidence of endometrial cancer in the United States. N Engl J Med (1976) 2.14
Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci (2001) 1.87
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75
Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst (1999) 1.73
Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol (2007) 1.65
Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol (2004) 1.63
Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer (2010) 1.52
Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ (1989) 1.39
The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am (2011) 1.34
Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol (2006) 1.27
Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev (2005) 1.19
Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol (1987) 1.11
Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol (2012) 1.10
Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer (1989) 1.09
Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer (2007) 1.08
Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer (2012) 1.07
Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol (2010) 1.06
Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol (2000) 1.05
Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.04
Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J R Soc Med (1979) 1.01
Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol (1979) 1.00
Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev (2012) 0.94
Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol (2000) 0.92
Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev (2004) 0.91
Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control (2003) 0.91
Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol (1980) 0.89
Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer (2011) 0.89
Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol (1993) 0.88
Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects. Maturitas (1985) 0.88
Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control (2001) 0.87
Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Saf (2005) 0.85
Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol (1990) 0.85
Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol (2009) 0.83
Progestogen modification of endometrial histology in menopasual women. Br Med J (1978) 0.83
The modifying effect of progestogen on the response of the post-menopausal endometrium to exogenous oestrogens. Postgrad Med J (1978) 0.83
Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Cancer Causes Control (2007) 0.83
Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control (2011) 0.83
Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology (1998) 0.81
Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control (1996) 0.81
Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol (2004) 0.80
Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas (1988) 0.77
Carcinoma of the endometrium in patients treated with tibolone. Gynecol Oncol (2004) 0.76
Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas (2002) 0.76